Diagnostic Trial to Validate the Use of the E-Nose in Pulmonary TB

Tuberculosis, Pulmonary Clinical Trial

Official title:

Diagnostic Trial to Validate the Use of the E-Nose in Pulmonary TB

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02768909
• Other study ID #: EN001
• Status: Active, not recruiting
• Phase: N/A
• First received: April 11, 2016
• Last updated: May 9, 2016
• Start date: January 2015
• Est. completion date: February 2017

Study information

• Verified date: May 2016
• Source: Universidad Central de Venezuela
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Determine the diagnostic accuracy for pulmonary tuberculosis in adults of the E-Nose in Venezuela.

Description:

Acronyms:

Tuberculosis (TB) Receiver Operating Curve (ROC) Common Terminology Criteria for Adverse Effects (CTCAE)

The aim of the study is to determine the diagnostic utility of the device 'Electronic Nose' for Pulmonary Tuberculosis. Prospective, Open, Three - Arm Controlled trial Study. Validation of the E-nose in urban settings to estimate the diagnostic accuracy of the E-nose using exhaled air in patients with Pulmonary TB in adults.

The patients who qualified for the study, according to the inclusion criteria, after consenting, will be guided through and oriented survey for risk factors, then a complete physical exam, and after that, the patient will breathe for 5 minutes trough the device, which stores the patient information, that later will be download to a computer and will be send to the server's manufacturer company, in Netherlands.

During and after the use of the device, we determine the adverse effects of the intervention, according to the CTCEA.

The researchers use the sputum culture, which is the gold standard, to determine the diagnostic utility of the test. And, will compare the results with other tests currently perform as the regular diagnostic routine, such as Chest X-ray, sputum smear, and symptom based diagnosis.

The patients in the experimental group are invited to come during the treatment phase, and will be asses the progress of the treatment, as well as another use of the device, at 5, 15, 30, 60 days after initiation of treatment, and will be compared the results of the device, with symptoms, x-ray changes, improvement of anthropometric findings, to determine the utility of the device to measure the response to treatment.

Patient Registries will be keep in an electronic database, as well as handwriting history, with the backup copy in the records of the hospital in which the patient was admitted.

auditoriae will be realised by the Ethics Comite in different time frames.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 250
• Est. completion date: February 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• Accept to participate in the study through a signed informed consent approved by the Ethical Committee of our Institution.

• More than 15 years old.

• People with a culture positive for pulmonary TB

Exclusion Criteria:

• Severe compromise of the general condition.

• Not capable to exhaled through the E-nose.

• No possibility to follow-up.

• By discretion of the research team.

Related Conditions & MeSH terms

• e-Nose
• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Device:
• E-Nose
1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.

Other:
• Survey & Physical Exam
2. Perform a oriented survey for risk factors and a complete physical exam.
• Chest X-ray
Perform anteroposterior chest X-ray
• Sputum Samples
Sputum samples for Ziehl Neelsen smear and Culture in L-J.

Device:
• Follow Up 5 days after beginning of Tx.
Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device. Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment.
• Follow Up 15 days after beginning of Tx.
Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device. Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment.
• Follow Up 30 days after beginning of Tx.
Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device. Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment.
• Follow Up 60 days after beginning of Tx.
Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device. Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment.

Locations

Country	Name	City	State
Venezuela	Instituto de Biomedicina	Caracas	DC

Sponsors (3)

Lead Sponsor	Collaborator
Universidad Central de Venezuela	Fundación Para la Investigación en Micobacterias (FUNDAIM), The ENose Company, Zutphen, Netherlands

Country where clinical trial is conducted

Venezuela, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic Accuracy of the electronic nose signal value to differentiate patients with Pulmonary TB.	Sensitivity, Specificity and Predictive Values; calculated with an ROC curve based on the Average processed-signal of the three electronic nose sensors. The signal is generated with a complex pattern recognition software, measuring the adsorption rate, desorption rate, and area under the curve generated by each sensor, expressed with a single value that ranges between -1 to +1.	1 year
Primary	Average Days needed to observed a negative result with the device after initiation of treatment.	Days-to-negative.	60 days
Secondary	Number of Adverse Effects related to the used of the device, assess by the CTCAE		1 year